Management reaffirmed the expectation to support business operations into the fourth quarter of 2027 on current resources, excluding potential product revenue or monetization of a priority review ...
CNTY-813, lead beta islet cell therapy program as a potential functional cure for type 1 diabetes, in Investigational New Drug (IND)-enabling studies; IND submission expected in 4Q 2026 to support ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results